Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07646080 | Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans | not yet recruiting | Phase 2 | 20 | Yanjie Zhang, MDOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 |
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03890068 | Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma | completed | Phase 2 | 49 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04589741 | Toripalimab Combined With CAV/IE Regimen | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | terminated | Phase 2 | 8 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04172805 | Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma | completed | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03719430 | APX005M and Doxorubicin in Advanced Sarcoma | completed | Phase 2 | 27 | Alexander Z. Wei, MDOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06087861 | 5-Day Preoperative Radiation for Soft Tissue Sarcoma | recruiting | Phase 2 | 75 | Stanford UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT04871282 | A Study of AL102 in Patients With Progressing Desmoid Tumors(RINGSIDE) | active not recruiting | Phase 2 / Phase 3 | 198 | Immunome, Inc.INDUSTRY | 11 | Jun 8, 2026 | clinicaltrials |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | terminated | Phase 2 | 11 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05167994 | Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）(SPARE-01) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06022159 | A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.(HYPOSARC) | recruiting | Phase 2 | 48 | Institut Claudius RegaudOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT07612098 | Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma(SPARE-04) | not yet recruiting | Phase 2 | 274 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03114527 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | active not recruiting | Phase 2 | 48 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07434843 | PH 2 Pemigatinib in SDH-deficient GIST(PEMIGIST) | recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07467772 | Ph 2 Elacestrant in ER Positive Uterine Sarcomas | recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07602049 | Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05301764 | A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 39 | Lyvgen Biopharma Holdings LimitedINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT06094101 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)(PerVision) | recruiting | Phase 1 / Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04605770 | Pemetrexed, Cisplatin With Soft Tissue Sarcoma(ALBATROSS) | recruiting | Phase 2 | 164 | Yonsei UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07541430 | A Study in Adults With Desmoid Tumors | recruiting | Phase 2 | 50 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07550582 | Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction(SAVE-GEJ) | enrolling by invitation | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07243626 | Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04216953 | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma(COTESARC) | completed | Phase 1 / Phase 2 | 229 | Centre Leon BerardOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04095208 | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study(CONGRATS) | completed | Phase 2 | 68 | Institut BergoniéOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 65 | University of Colorado, DenverOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04189783 | Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03601806 | Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | completed | Phase 2 | 26 | AIDS Malignancy ConsortiumNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05926700 | Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05661643 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST(GIST) | recruiting | Phase 2 | 29 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05905887 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06326346 | GIST Oral Paclitaxel(Liporaxel) | recruiting | Phase 2 | 28 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 16, 2026source: clinicaltrials